Patenting and Licensing. For VA: Department of Veterans Affairs Director, Technology Transfer (10X2TT) 000 Xxxxxxx Xx XX Washington, DC 20420 Email: XXXXXXXX@xx.xxx; Telephone: (000) 000-0000; For Collaborator:
Patenting and Licensing. For VA: Department of Veterans Affairs Director, Technology Transfer (12TT) 000 Xxxxxxx Xx XX Xxxxxxxxxx, XX 00000 Email: Xxx.Xxxxxxxx@xx.xxx; Telephone: (000) 000-0000; Fax: (000) 000-0000 For Collaborator: AVEO Pharmaceuticals, Inc. 00 Xxxxxx Xxxxxx Cambridge, MA 02139 Attn: VP, Intellectual Property SIGNATURES ARE FOUND ON THE NEXT PAGE. VA PII CRADA MODEL 8AUG08 Page 13 of 13 SIGNATURE PAGE ACCEPTED AND AGREED: By executing this agreement, each Party represents that all statements made herein are true, complete, and accurate to the best of its knowledge; that each has read and understood this CRADA prior to signing; and that each enters into it freely and voluntarily. FOR COLLABORATOR 9/8/11 Date /s/ Xxxxxx Xxxx Signature Xxxxxx Xxxx, PhD Typed Name Vice President, Translational Medicine Title FOR VA: /s/ Xxxx Xxxxxx 9-19-11 Signature (NPC Executive Director or Other Authorized Signatory) Date Xxxxxxx Xxxxxx Typed Name Executive Director Title Principal Investigator Acknowledgement While not a Party, I understand and agree to the Principal Investigator obligations stated in this Agreement. Further, I certify that I am not debarred under subsections 306(a) or (b) of the Federal Food, Drug, and Cosmetic Act and shall not use in any capacity the services of any person debarred under such law with respect to services to be performed under this Agreement. I also certify that I am not excluded from any Federal health care program, including but not limited to Medicare and Medicaid. /s/ Xxxx Xxxxxx Principal Investigator Signature Xxxx X Xxxxxx MD, PhD Principal Investigator Name VA CT CRADA Appendices MODEL 5/2007 Department of Veterans Affairs PRINCIPAL INVESTIGATOR INITIATED STUDY COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA) APPENDIX A-1 CRADA PERIOD OF PERFORMANCE The term of this CRADA shall begin as of the date of the last signature of the Parties and shall terminate when the statement of work is completed VA CT CRADA Appendices MODEL 5/2007 Department of Veterans Affairs PRINCIPAL INVESTIGATOR INITIATED STUDY COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA) APPENDIX A-2 CRADA STATEMENT OF WORK (PROTOCOL) Scope of Work for collaboration between Xx. Xxxx X Garcia, MD, PhD and AVEO Pharmaceuticals Title: Biomarker evaluation for cachexia inducing/mediating factors in plasma from cancer patients Background Symptoms including cachexia (involuntary weight loss), anorexia (decreased appetite and food intake) and poor functional performance aff...
Patenting and Licensing. Patenting and Licensing of inventions generated by NCI Investigators (whether intramural or extramural) conducting the Research Plan will be managed in a manner consistent with the IP Option. In addition, inventions generated during Secondary Research conducted by investigators, including NIH Intramural Investigators, will be subject to the terms of the IP Option.
